Tripod Therapeutics

Company Overview

Snapshot

Founded in September 2022 by Dr. Ido Livneh and Prof. Aaron Ciechanover, Tripod Therapeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing novel cancer therapies.

Business overview

Tripod Therapeutics is a biopharmaceutical company specializing in the manipulation of proteasome dynamics to treat cancer. Based on scientific research by Nobel Prize Laureate Prof. Aaron Ciechanover, the company is developing an orally available drug substance designed to regulate proteasome localization, thereby inducing cancer cell death. Tripod Therapeutics serves the healthcare and life sciences industries, specifically targeting the pharmaceutical sector with its drug discovery and development efforts in oncology.

Company Intelligence Q&A

What is Tripod Therapeutics' core focus?

Tripod Therapeutics specializes in harnessing proteasome dynamics for cancer treatment, developing an orally available drug to regulate proteasome localization and induce cancer cell death.

When was Tripod Therapeutics founded?

Tripod Therapeutics was founded in September 2022.

Who are the founders of Tripod Therapeutics?

Tripod Therapeutics was founded by Dr. Ido Livneh and Prof. Aaron Ciechanover.

What is the current employee size of Tripod Therapeutics?

Tripod Therapeutics currently has 1–10 employees.

What is Tripod Therapeutics developing?

Tripod Therapeutics is developing an orally available drug substance designed to regulate proteasome localization, thereby inducing cancer cell death. The company has demonstrated its efficacy in several animal models of cancer and is working towards pre-clinical and clinical studies.